The treatment of central diabetes insipidus has not changed significantly in recent decades, and dDAVP and replacement of free water deficit remain the cornerstones of treatment. Oral dDAVP has replaced nasal dDAVP as a more reliable mode of treatment for chronic central diabetes insipidus. Hyponatraemia is a common side effect, occurring in one in four patients, and should be avoided by allowing a regular break from dDAVP to allow a resultant aquaresis. Hypernatraemia is less common, and typically occurs during hospitalization, when access to water is restricted, and in cases of adipsic DI. Management of adipsic DI can be challenging, and requires initial inpatient assessment to establish dose of dDAVP, daily fluid prescription, and eunatraemic weight which can guide day-to-day fluid targets in the long-term.

在最近的几十年中，中枢性尿崩症的治疗没有显着变化，dDAVP和补充游离水缺乏症仍然是治疗的基石。口服dDAVP已取代鼻dDAVP，成为治疗慢性中枢性尿崩症的更可靠方法。低钠血症是一种常见的副作用，发生在四分之一的患者中，应通过定期与dDAVP休息以避免发生水肿来避免。高钠血症较不常见，通常发生在住院期间，饮水受到限制以及脂肪性DI的情况下。脂肪性DI的管理可能具有挑战性，需要进行初始住院评估以确定dDAVP的剂量，每日输液处方和非血液性体重，这些指标可以长期指导日常的输液目标。